BR112023019464A2 - Anticorpo que tem como alvo cd22 e cd79b - Google Patents

Anticorpo que tem como alvo cd22 e cd79b

Info

Publication number
BR112023019464A2
BR112023019464A2 BR112023019464A BR112023019464A BR112023019464A2 BR 112023019464 A2 BR112023019464 A2 BR 112023019464A2 BR 112023019464 A BR112023019464 A BR 112023019464A BR 112023019464 A BR112023019464 A BR 112023019464A BR 112023019464 A2 BR112023019464 A2 BR 112023019464A2
Authority
BR
Brazil
Prior art keywords
cd79b
targets
antibody
vectors
bind
Prior art date
Application number
BR112023019464A
Other languages
English (en)
Inventor
Danlin Yang
Kyle Bednar
Naresh Kumar
Rajkumar Ganesan
Sanjaya Singh
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of BR112023019464A2 publication Critical patent/BR112023019464A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

são aqui fornecidos anticorpos multiespecíficos, que se ligam a cd79b e cd22, polinucleotídeos que os codificam, vetores, células hospedeiras, métodos para produzir e usar estes.
BR112023019464A 2021-03-24 2022-03-23 Anticorpo que tem como alvo cd22 e cd79b BR112023019464A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163165416P 2021-03-24 2021-03-24
PCT/IB2022/052645 WO2022201052A1 (en) 2021-03-24 2022-03-23 Antibody targeting cd22 and cd79b

Publications (1)

Publication Number Publication Date
BR112023019464A2 true BR112023019464A2 (pt) 2023-12-05

Family

ID=80978877

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023019464A BR112023019464A2 (pt) 2021-03-24 2022-03-23 Anticorpo que tem como alvo cd22 e cd79b

Country Status (13)

Country Link
US (1) US20220306738A1 (pt)
EP (1) EP4314055A1 (pt)
JP (1) JP2024512035A (pt)
KR (1) KR20230160314A (pt)
CN (1) CN117098781A (pt)
AR (1) AR125210A1 (pt)
AU (1) AU2022244453A1 (pt)
BR (1) BR112023019464A2 (pt)
CA (1) CA3214259A1 (pt)
IL (1) IL306103A (pt)
TW (1) TW202304986A (pt)
UY (1) UY39683A (pt)
WO (1) WO2022201052A1 (pt)

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
TWI313299B (en) 2000-11-30 2009-08-11 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
CA2646965C (en) 2006-03-24 2016-06-21 Jonathan H. Davis Engineered heterodimeric protein domains
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
AU2007335663B2 (en) 2006-12-18 2011-12-15 Link Genomics, Inc. Helicobacter pylori eradicating agent having inhibitory activity on gastric acid secretion
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
CA2710373A1 (en) 2007-12-19 2009-07-09 Ping Tsui Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
US20100261620A1 (en) 2008-10-14 2010-10-14 Juan Carlos Almagro Methods of Humanizing and Affinity-Maturing Antibodies
WO2010051274A2 (en) 2008-10-31 2010-05-06 Centocor Ortho Biotech Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
RU2562700C2 (ru) 2009-02-12 2015-09-10 Янссен Байотек, Инк. Композиции, способы получения и применение каркаса на основе домена фибронектина типа iii
CA2759233C (en) 2009-04-27 2019-07-16 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
KR102152109B1 (ko) 2010-04-20 2020-09-07 젠맵 에이/에스 이종이량체 항체 ｆｃ-함유 단백질 및 그의 생산 방법
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
JP6167040B2 (ja) 2010-11-05 2017-07-19 ザイムワークス，インコーポレイテッド Ｆｃドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
SG10201805291TA (en) 2011-10-27 2018-08-30 Genmab As Production of heterodimeric proteins
MX358862B (es) 2011-11-04 2018-09-06 Zymeworks Inc Diseño de anticuerpo heterodimérico estable con mutaciones en el domino fc.
SG11201507577RA (en) 2013-03-15 2015-10-29 Janssen Biotech Inc Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins
GB201412658D0 (en) * 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201601077D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
JP7095078B2 (ja) 2017-09-22 2022-07-04 カイト ファーマ インコーポレイテッド キメラポリペプチド及びその使用
WO2021099944A1 (en) * 2019-11-18 2021-05-27 Janssen Biotech, Inc. Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof

Also Published As

Publication number Publication date
TW202304986A (zh) 2023-02-01
US20220306738A1 (en) 2022-09-29
WO2022201052A1 (en) 2022-09-29
EP4314055A1 (en) 2024-02-07
UY39683A (es) 2022-09-30
CA3214259A1 (en) 2022-09-29
AU2022244453A1 (en) 2023-11-09
AU2022244453A9 (en) 2023-11-16
KR20230160314A (ko) 2023-11-23
IL306103A (en) 2023-11-01
AR125210A1 (es) 2023-06-21
JP2024512035A (ja) 2024-03-18
CN117098781A (zh) 2023-11-21

Similar Documents

Publication Publication Date Title
PE20170263A1 (es) Moleculas biespecificas de union a antigeno activadoras de celulas t
AR117392A1 (es) Anticuerpos de unión a gprc5d
UY37340A (es) Antianticuerpos gprc5d, moléculas de unión al antígeno biespecíficas que se unen a gprc5d y cd3, y usos de estas
MX2020004149A (es) Variantes de desoxirribonucleasa (dnasa).
BR112019007288A2 (pt) proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente
PE20180798A1 (es) Constructos de anticuerpos biespeficos que se unen a mesotelina y cd3
PE20171764A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123
PE20211603A1 (es) Anticuerpos que se unen a cd3
CR10652A (es) Anticuerpos monoclonales humanos especificos para light humano antagonistas
UY39634A (es) Anticuerpo triespecífico dirigido a bcma, gprc5d, y cd3
AR120857A1 (es) Anticuerpos que se unen a hla-a2 / mage-a4
CL2022003638A1 (es) Anticuerpos que se unen a cd3
AR113223A1 (es) Anticuerpo monoclonal para pd-l1
AR080873A1 (es) Anticuerpos contra factor de crecimiento epidermico (anti-erbb3 o anti-her3)
CO6450618A2 (es) Anticuerpos especificos para cadherina-17
CL2012002081A1 (es) Anticuerpo humanizado que se une a la cadena alfa del receptor de il-7 humano (cd127); proteina de enlace a antigeno que comprende una o mas regiones determinantes de complementariedad de dicho anticuerpo; molecula de acido nucleico que codifica una anticuerpo o proteina de enalce; vector de expresion, celula huesped recombinante; procedimiento para la produccion de una proteina de enlace a antigeno; procedimiento para tratar enfermedad autoinmune o inflamatoria.
BR112013009551A2 (pt) anticorpos
AR100255A1 (es) Un factor de secreción de proteínas con alta eficiencia secretora y un vector de expresión que lo comprende
CU24320B1 (es) Anticuerpos conjugados contra antígeno linfocitario 75 para el tratamiento del cáncer
CL2021001835A1 (es) Neoantígenos prostáticos y sus usos.
EA201892060A1 (ru) Микробная продукция рибозида никотиновой кислоты
ECSP19026593A (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos
CO2023010208A2 (es) Proteínas de unión a psma y usos de estas
AR114001A1 (es) Anticuerpos que se unen a hla- a2 / wt1
CO2020005371A2 (es) Anticuerpos anti-apoc3 y métodos de uso de estos